Full-Time

Manager – IT Business Analysis

R&D IT Research Business Systems

Posted on 8/23/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$146.5k - $189.6k/yr

+ Bonus + Stock-based long-term incentives

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

In Person

Category
Biology & Biotech (5)
, , , ,
Requirements
  • 6+ years’ relevant experience with BS / BA
  • 4+ years’ relevant experience with MS / MA / MBA
  • Biological Sciences, Bioinformatics, Computer Science or a related discipline is preferred.
  • Significant IT experience in a corporate or other relevant business environment, with a strong preference for experience in the biopharmaceutical or healthcare industry.
  • Experience supporting IT business systems analysis, planning, budgeting and coordination of IT resources to support R&D needs in life sciences.
  • Demonstrated experience in business process engineering and project management.
  • Experience with IT integrations, cloud transformations, and understanding of data security and compliance issues in a scientific or healthcare setting.
  • Direct experience or strong familiarity with drug discovery research and bioinformatics tools and technologies used in various therapy areas is highly desirable.
  • Proven ability to work collaboratively with cross-functional teams, including scientists, researchers, and non-IT personnel, to translate scientific research needs into IT solutions.
Responsibilities
  • Oversee and manage the gathering of business and user requirements, conducting thorough needs analysis to ensure alignment with scientific research goals and IT capabilities.
  • Analyze initial business cases, including resource requirements, categorization, and prioritization, to support strategic IT initiatives in pharmaceutical research.
  • Conduct assessments of current business processes, systems, and applications, recommending improvements based on business needs, industry trends, and best practices.
  • Document business process flows for current and future states, ensuring clarity and efficiency in processes that bridge IT and research operations.
  • Manage the documentation of user requirements and use cases, facilitating clear communication between IT teams and research scientists.
  • Provide timely and appropriate analysis to development teams for the definition of functional requirements, ensuring technology solutions meet research needs.
  • Collaborate on request for proposal (RFP) submissions and responses, evaluate vendors, and ensure contract readiness, including compliance with regulatory requirements like GxP and SOX.
  • Participate in design reviews, contributing to the development of digital solutions that enhance drug development efforts.
  • Oversee and manage the creation of test scenarios, ensuring comprehensive coverage of user requirements and system functionalities.
  • Support user acceptance testing (UAT) by reviewing test results and collaborating with technical teams on issue resolution, ensuring solutions meet user expectations.
  • Coordinate project roll-out and deployment, including defining implementation requirements, managing communications, and conducting end-user training.
  • Conduct value affirmation analysis post-project implementation to assess the impact and effectiveness of IT solutions in supporting drug discovery and development.
  • Manage enhancements and defect analysis, providing recommendations for resolution to maintain and improve digital solutions.
  • Oversee vendor deliverables related to projects, ensuring quality and compliance with contractual agreements.
  • Ensure all assigned work complies with established practices, policies, and processes, adhering to regulatory and other requirements to maintain the integrity and security of research data.
Desired Qualifications
  • Demonstrated expertise in technology environments relevant to pharmaceutical research, including familiarity with bioinformatics and computational biology platforms (e.g. Visiopharm, Genedata Profiler, DNA Nexus, etc.).
  • Demonstrated understanding of design, solution development methods, and the Project Execution Process, including comprehensive knowledge of requirement specification, system/application design, development, configuration, and testing.
  • Proven experience in applying best practices in IT project management, continuous improvement, and change management, with a preference for experience in highly regulated environments such as the biopharmaceutical industry.
  • Experience with platforms critical to drug discovery Research and Development (e.g., Biovia, Benchling, Genedata, etc.) and a willingness to learn and adapt to new R&D IT systems as they emerge.
  • Extensive knowledge of Agile methodologies and tools (e.g. Jira, Asana, etc.), with proven abilities to apply these in supporting IT solutions that meet both business needs and scientific research objectives.
  • Thorough understanding of the Software Development Life Cycle (SDLC) and Service Life Cycle (SLC), with particular attention to their application in life sciences research IT projects.
  • Experience in programming environments (e.g., Python, R) and cloud computing platforms (e.g., AWS), especially those relevant to data analytics and computational research in life sciences is very desirable.
  • Good understanding of IT security, quality, and risk management, particularly in the context of handling sensitive scientific data and PHI/PII is required.
  • Strong troubleshooting skills with existing technologies and a strategic approach to managing integrations between various IT systems to optimize research operations.
  • Ability to apply basic architectural principles in technology recommendations and decisions, with a focus on scalability and sustainability of IT solutions for research.
  • Proficiency in applying UX principles to ensure that IT solutions are user-centric, facilitating seamless interaction for researchers and scientists.
  • Keen awareness of emerging IT trends and technologies (e.g. GenAI, Precision Medicine, Digital Biomarkers, etc.), with a commitment to continuous learning, especially in areas relevant to biopharmaceutical research.
  • Demonstrated ability to quickly grasp regulatory requirements, including GDPR, HIPAA, and others pertinent to the biopharma industry, and integrate compliance into IT solutions.
  • Flexibility and adaptability to change, capable of transitioning smoothly between projects and contributing expertise as needed across various IT and research domains.
  • Strong analytical skills, high attention to detail, excellent communication, and organizational skills, with the ability to lead and influence cross-functional teams in a research-driven environment.
  • Willingness to travel as required to support project needs and facilitate collaboration across different research sites.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • HIV franchise grows 10% YoY to $20.8 billion in 2025 with no patent cliffs until 2036.
  • Trodelvy oncology sales surge 37% to $253 million in Q1 2026 ahead of H2 expansions.
  • $11.5 billion acquisitions of Arcellx, Ouro, Tubulis add 53-programme pipeline launches by 2027.

What critics are saying

  • Florida delists Biktarvy from AIDS program in May 2026, slashing $20.8 billion HIV revenue.
  • $11.5 billion acquisition charges flip 2026 EPS to $1.05 loss, integration fails by 2027.
  • Biktarvy generics erode 40% revenue post-2034 as regulatory pathways accelerate competition.

What makes Gilead Sciences unique

  • Gilead pioneered complete once-daily HIV regimens like Biktarvy generating $14.3 billion in 2025.
  • Gilead leads with twice-yearly HIV prevention via Yeztugo reaching $166 million Q1 2026 sales.
  • Gilead dominates antiviral therapies across HIV, hepatitis, and COVID-19 since 1987 founding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

AllSci
Apr 10th, 2026
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access.

Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access. April 10, 2026 Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at advancing Gilead's oncology pipeline through enterprise-wide access to Tempus's AI-driven Lens platform and multimodal real-world evidence datasets. The agreement covers multiple oncology indications; no specific drug candidates or therapeutic targets were disclosed as part of the transaction. Financial terms were not disclosed. Under the expanded arrangement, Gilead gains enterprise-wide access to the Tempus Lens platform, which integrates de-identified genomic, clinical, imaging, and outcomes data into a unified repository supported by AI-driven analytical tooling. Disclosed applications include trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence generation. Tempus will also provide dedicated analytical services under the agreement. The collaboration represents an expansion of a pre-existing relationship in which Gilead had previously used Tempus data to inform oncology R&D initiatives, and follows on from a collaboration between Tempus and Daiichi Sankyo announced in March 2026. The collaboration is designed to operate across Gilead's oncology pipeline rather than in support of a single program. Gilead's oncology portfolio includes sacituzumab govitecan, axicabtagene ciloleucel, brexucabtagene autoleucel, and magrolimab, among other assets, though none were named as specific beneficiaries of the arrangement. The platform's stated functions - indication prioritization, patient stratification, biomarker pre-validation, and real-world evidence generation - are applicable across tumor types and development stages. Your email address will not be published. Required fields are marked *

Yahoo Finance
Apr 9th, 2026
Gilead exercises option on Kymera's oral CDK2 degrader KT-200, triggering $45M milestone

Kymera Therapeutics will receive a $45 million milestone payment following Gilead Sciences' decision to exercise its option to exclusively licence KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate. Gilead will advance the programme into IND-enabling studies, targeting an IND filing in 2027. KT-200 is expected to become the first molecular glue discovered by Kymera to enter clinical trials. The drug candidate demonstrated low-nanomolar degradation of CDK2 in preclinical testing, with robust activity in cancer cell lines and favourable safety profiles. It targets cancers driven by CCNE1 amplification, including advanced breast cancer. Under their collaboration agreement, Kymera is eligible for up to $750 million in total payments and has received $85 million to date. The company will also receive tiered royalties on net product sales.

Genetic Engineering and Biotechnology News
Apr 7th, 2026
Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities.

Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities. April 7, 2026 Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer's antibody-drug conjugate (ADC) capabilities with a focus on fighting cancer. Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies intended to more selectively deliver diverse payloads to tumors deemed to be of high unmet need. The companies said Tubulis' programs and platforms have broad potential across multiple tumor types, complementing Gilead's development and commercialization expertise in oncology. "We like the strategic fit and deal terms of the Tubulis (private) acquisition," Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst at Leerink Partners, wrote this morning in a research note. "This is more than an oncology bolt-on; we see real platform value in application of Tubulis' ADC technologies to other therapeutic areas, namely virology." Tubulis' lead pipeline candidate, TUB-040, is a sodium-dependent phosphate transport protein 2B (NaPi2b)-targeting topoisomerase-I inhibitor (TOPO1i) ADC that is now under study in the Phase Ib/II NAPISTAR1-01 trial (NCT06303505) assessing its safety, pharmacokinetics, and preliminary efficacy as a treatment for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In October at the European Society for Medical Oncology (ESMO), Graybosch noted, Tubulis presented data for TUB-040 showing a confirmed 50% overall response rate (ORR) and a 60% unconfirmed ORR across dose levels and irrespective of target antigen - results that were competitive with more mature datasets from leading TOPO1i ADCs. "Though the dataset was early, and our primary outgoing question was how durability would mature, we suspect that Gilead saw durability maturing positively in their diligence," Graybosch added. "If TUB-040 proves active in NSCLC, the program could complement their Trodelvy and IO [immune-oncology] lung programs. We wonder if Gilead saw early clinical NSCLC data in their diligence and if excitement around the emerging signal drove some of Tubulis' valuation." Another Tubulis pipeline candidate, TUB-030, is a 5T4-targeting ADC that according to the companies has shown promising initial clinical data across various solid tumor types. TUB-030 is currently under study in the Phase I/IIa 5-STAR 1-01 trial (NCT06657222), a first-in-human study which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 as a monotherapy in patients with advanced solid tumors. Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications. Partners since 2024. The acquisition deal follows a two-year, up-to-$465 million collaboration with Tubulis launched in December 2024. Gilead gained access to Tubulis' Tubutecan and Alco5 platforms after signing an exclusive option and license agreement to discover and develop an ADC against a solid tumor target. At the time, Gilead agreed to pay Tubulis $20 million upfront, received an option that if exercised would have given Tubulis an additional $30 million - plus up to $415 million in payments tied to achieving development and commercialization milestones, as well as mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. "Today's agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities," Gilead Chairman and CEO Daniel O'Day said in a statement. "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline." "Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company's history," O'Day declared. Investors appeared less enthusiastic about the acquisition, as shares of Gilead dipped 1.7% in early Tuesday trading to $137.80 as of 12:01 p.m. ET. Tubulis is Gilead's third announced acquisition this year. The biotech giant announced plans in March to buy Ouro Medicines for up to $2.18 billion, and in February agreed to acquire Arcellx for up to $7.8 billion - for which it agreed last week to extend its tender offer until 5 p.m. ET on April 24. Under the acquisition deal, Gilead agreed to acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash payable at closing, and up to $1.85 billion in payments tied to milestones. The transaction is expected to close in the second quarter subject to expiration or termination of specified regulatory filings and other customary conditions. Upon closing of the deal, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Gilead said it plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Gilead finished 2025 with $10.605 billion of cash, cash equivalents and marketable debt securities, up from $9.991 billion as of December 31, 2024.

Dealroom.co
Apr 7th, 2026
Gilead Sciences company information, funding & investors

Gilead Sciences, biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases. Here you'll find information about their funding, investors and team.

Mednext Healthcare
Apr 7th, 2026
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion.

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion. Up next. Published on 07 April 2026 EQT Life Sciences plans to sell its stake in Tubulis to Gilead Sciences. * EQT Life Sciences sells stake in Tubulis to Gilead Sciences. * The transaction could be valued at up to $5 billion. * This sale marks a significant shift in EQT's investment strategy. EQT Life Sciences is preparing to sell its minority stake in the biopharmaceutical company Tubulis to Gilead Sciences. This strategic move is expected to generate a total value of up to $5 billion. The transaction highlights the growing interest by major firms in innovative therapeutic developments. Gilead Sciences aims to leverage Tubulis's advancements in biopharmaceuticals through this acquisition. The sale reflects EQT Life Sciences' approach to capitalizing on its investments in the life sciences sector. Both companies anticipate that this deal will accelerate the delivery of critical therapies to patients. As part of this transaction, EQT Life Sciences is expected to reallocate its resources towards new investment opportunities within the life sciences arena. The sale aligns with industry trends favoring the consolidation of innovative technologies in the biopharmaceutical space.

INACTIVE